For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach. In the last 5 years alone, the approval and adoption of Next-Gen Sequencing (NGS) in oncology has helped advance the field. As NGS has evolved from a limited luxury to a common component of the physician toolkit, our future is now. View where the course has been securely mapped out, and where uncharted territory still exists...

Cruise Control: High NGS use >60%
Light Speed: <60% use, but high growth >25%
Warp Speed: High NGS use (>60%) AND high growth (>25%)
Mission Critical: Tumors with NGS use below 50%

US and China are robust adopters of Next-Generation Sequencing. The FDA made the first approval for a pan-tumor NGS test in 2017. Currently, US guidelines recommend NGS testing for many tumor types and multiple testing platforms are available, all of which has led to high adoption rates of NGS in the US.

China has a booming genomics market and a clear pathway for NGS testing platforms to gain approval. Since 2018, multiple NGS panels have been approved by the NMPA, including domestically-developed options, leading to significant adoption rates of NGS in China.

Across all regions, NGS utilization is highest in AML and NSCLC patients, while prostate cancer is consistently the tumor with the lowest use of NGS testing.

Mission Synopsis

US and China are robust adopters of Next-Generation Sequencing. The FDA made the first approval for a pan-tumor NGS test in 2017. Currently, US guidelines recommend NGS testing for many tumor types and multiple testing platforms are available, all of which has led to high adoption rates of NGS in the US.

China has a booming genomics market and a clear pathway for NGS testing platforms to gain approval. Since 2018, multiple NGS panels have been approved by the NMPA, including domestically-developed options, leading to significant adoption rates of NGS in China.

Across all regions, NGS utilization is highest in AML and NSCLC patients, while prostate cancer is consistently the tumor with the lowest use of NGS testing.

Precision Medicine: The Next Generation

CancerMPact® – Treatment Architecture™ - Published and unpublished data collected from 2019 – 2021.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
CancerMPact®: Improving outcomes through empowered decision making.
Start or continue your journey here.